Axsome Therapeutics
AXSM
35 hedge funds and large institutions have $13.1M invested in Axsome Therapeutics in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 6 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
27% more capital invested
Capital invested by funds: $10.4M → $13.1M (+$2.75M)
0.64% less ownership
Funds ownership: 16.61% → 15.97% (-0.64%)
3% less funds holding
Funds holding: 36 → 35 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
62% less call options, than puts
Call options by funds: $55K | Put options by funds: $145K
Top Buyers
| 1 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$478K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$145K |
| 3 |
VF
Virtu Financial
New York
|
+$57.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$48.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$31K |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$306K |
| 2 |
RA
Royce & Associates
New York
|
-$209K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$199K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$117K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$91K |
AXSM Hedge Fund Activity: Q2 2018 in Review
35 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2018, worth a combined $13.1M — up 27% from $10.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of AXSM and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 8 added.
The largest buyer was Alethea Capital Management, adding an estimated $478K. The largest seller was JP Morgan Chase, cutting an estimated $306K.
- 35 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2018, down from 36 in Q1 2018.
- Funds reported $13.1M of Axsome Therapeutics stock for Q2 2018, up 27% quarter-over-quarter.
- 5 funds opened new Axsome Therapeutics positions in Q2 2018 and 6 closed out, a net change of -1 holder.
- The largest Axsome Therapeutics buyer in Q2 2018 was Alethea Capital Management, an estimated $478K added.
- The largest Axsome Therapeutics seller in Q2 2018 was JP Morgan Chase, an estimated $306K sold.
Based on aggregated 13F filings for Q2 2018.